Table 3.
Factors affecting progression free survival. ECOG PS, Eastern Cooperative Oncology Group performance status
| Variable | Subgroup | Median PFS(95% CI) | P-value logrank |
|---|---|---|---|
| Age | Elderly | 46.0 (27.3–64.4) | 0.092 |
| Nonelderly | 68 (26.1–109.8) | ||
| Gender | Male | 64.0 (38.0–89.9) | 0.308 |
| Female | 55.0 (36.4–73.5) | ||
| ECOG PS | 0–1 | 98 (66.4–129.5) | 0.00 |
| 2–4 | 35 (27.4–42.5) | ||
| T size | < 5 cm | 68 (2.8–133.1) | 0.068 |
| ≥ 5 cm | 58.0 (42.1–73.8) | ||
| N stage | N0 | 61 (27.9–94.0) | 0.271 |
| N1 | 54 (36.2–71.7 | ||
| M stage | M0 | 61 (28.9–93.0) | 0.121 |
| M1 | 54 (31.4–76.5) | ||
| Hyperleukocytosis | No | 64 (37.3–90.6) | 0.436 |
| Yes | 45 (25.9–64.0) |